RxDoctor Payments Data

Bilal Ahmed, MD

Endocrinology, Diabetes & Metabolism · Bismarck, NDNPI 1720025034

Payments from drug & device makers

What this record shows

This record is dominated by grants: $6,667 of the $6,973 with a category attached, or 95.6%. Medtronic accounts for 95.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $6,735 and has fallen 97.8% since, to $145 in 2025.

$6,973in general payments, 2019–2025

Across 14 payments — averaging $498.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Dexcom, Inc.$87
  • Ipsen Biopharmaceuticals, Inc$44
  • Amgen$35
  • Corcept Therapeutics$29
  • Novo Nordisk$28
  • plus $68 from 3 others

What the payments were for

  • Grants$6,66796%
  • Food & beverage$3074%

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few endocrinology, diabetes & metabolism providers in North Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$23,624
Medicare patients
82
Services billed
455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$35,771
Tresiba Flextouch U-200Insulin Degludec18$21,545
TrulicityDulaglutide13$14,868
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$11,950
FarxigaDapagliflozin Propanediol13$8,580
Novolog FlexpenInsulin Aspart14$4,241
Levothyroxine Sodium224$3,400
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,238
SynthroidLevothyroxine Sodium17$1,322
Hydrocortisone39$1,307
Liothyronine Sodium12$504
Metformin Hcl28$309
Methimazole20$221
Atorvastatin Calcium12$151
Rosuvastatin Calcium11$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$28$35,77120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in North Dakotaon file to place this against a meaningful peer group, so we don't.

Other endocrinology, diabetes & metabolism in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →